Solvay Cert Refusal Leaves FCA Circuit Split In Place

Law360, New York (June 21, 2010, 12:13 PM EDT) -- The U.S. Supreme Court refused Monday to review the dismissal of a False Claims Act suit from two former Solvay Pharmaceuticals Inc. sales representatives who accused the drugmaker of using an off-label marketing campaign to boost sales of its THC compound, leaving a split among the circuit courts.

The high court denied the workers' petition for certiorari without further comment, letting stand a December decision from the U.S. Court of Appeals for the Eleventh Circuit finding the plaintiffs' FCA allegations deficient.

Relators James Hopper and Colin...
To view the full article, register now.